GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (OTCPK:LOBEF) » Definitions » Construction In Progress

LOBEF (Lobe Sciences) Construction In Progress : $0.00 Mil (As of Nov. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Lobe Sciences Construction In Progress?


Lobe Sciences Construction In Progress Historical Data

The historical data trend for Lobe Sciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Construction In Progress Chart

Lobe Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lobe Sciences Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lobe Sciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Lobe Sciences Business Description

Traded in Other Exchanges
Address
1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.